Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01915303 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT01915303 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 68 participants.
The verdict
NCT01915303, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
Interventions
- DRUG Pasireotide with or without cabergoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2014-03-06 |
| Est. Completion | 2019-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01915303
The ClinicalTrials.gov registry entry for NCT01915303 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pasireotide with or without cabergoline is the first listed.
NCT01915303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01915303 about?
NCT01915303 is a clinical study titled "Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease". The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
What is the current status of trial NCT01915303?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2014-03-06. Estimated completion is 2019-09-04.
What interventions are being tested in trial NCT01915303?
The interventions under investigation include: Pasireotide with or without cabergoline (DRUG).
Who is sponsoring clinical trial NCT01915303?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.